This rare case of convergent evolution shows nature arriving at the same mind-altering molecule by two separate paths. The true reason fungi produce psilocybin remains unsolved, but theories range from predator defense to chemical communication. Beyond evolutionary intrigue, the discovery also offers new enzyme tools that could help produce psilocybin more efficiently for future medicines.

Ancient Molecule With a Modern Role
“This concerns the biosynthesis of a molecule that has a very long history with humans,” explains Prof. Dirk Hoffmeister, head of the research group Pharmaceutical Microbiology at Friedrich Schiller University Jena and the Leibniz Institute for Natural Product Research and Infection Biology (Leibniz-HKI).

“We are referring to psilocybin, a substance found in so-called ‘magic mushrooms’, which our body converts into psilocin – a compound that can profoundly alter consciousness. However, psilocybin not only triggers psychedelic experiences, but is also considered a promising active compound in the treatment of therapy-resistant depression,” says Hoffmeister.

Two Evolutionary Paths to Psilocybin
The study, carried out within the Cluster of Excellence ‘Balance of the Microverse’, reveals that fungi developed the ability to produce psilocybin on at least two separate occasions in evolutionary history. Psilocybe mushrooms rely on a familiar set of enzymes to make the molecule, while fiber cap mushrooms use an entirely different biochemical toolkit. Despite these very different methods, both groups arrive at the same compound. Scientists call this convergent evolution, when unrelated species independently evolve the same trait.